[Significance of the determination of B2-glycoprotein-1 antibodies in recognizing the thrombogenicity in antiphospholipid syndrome].

According to the recent data, the determination of the higher titer of antibodies to beta2-glycoprotein-I (beta2-GP-I) that is included in a complex compound with negative phospholipid membranes determinates the thrombogenicity in antiphospholipid syndrome (APS). To specify this regularity, the authors examined 86 patients with primary APS and 20 patients with venous and arterial thrombosis without APS. With increased beta2-GP-I antibody levels, the incidence of thrombotic events was established to w significantly higher than in APS without the increased titer of beta2-GP-I antibodies.

[Changes of platelet aggregation in cancer patients].

Aggregation function of platelets was investigated in 119 patients with breast cancer, 17--gastric cancer and 11--cancer of large bowel. Levels of spontaneous and induced aggregation were abnormally high thus contributing to thrombophilic potential. Also, they were a factor of tumor progression and metastatic spread.

[Phlebothrombosis and pulmonary thromboembolism in patients with thrombophilia].

A study was made of the course of phlebothrombosis ana pulmonary thromboembolism in 54 patients with thrombophilia. Of these, 23 patients had factor la resistance to protein C, 15 presented with antiphospholipid syndrome, four with protein C deficit, one with protein S deficit, three with antithrombin III deficiency, and three patients with hyperhomocysteinemia. Five patients presented with the following combined forms of thrombophilia: thrombophilia due to protein C deficit and antiphospholipid syndrome; protein C deficit and hyperhomocysteinemia; protein C and antithrombin III deficit; factor Va resistance to protein C and hyperhomocysteinemia; antiphospholipid syndrome and hyperhomocysteinemia.

[Diagnostic procedure for thrombophilia due to factor VIII hyperproduction].

The range of factor Vlll (FVlll) is known to be very wide and its elevated concentration is a risk factor of thromboses. This paper describes a simple and available laboratory method for determining the high level of coagulation FVlll. Moreover, the results of determination of FVlll levels in 102 patients were used to study the incidence of thrombophilia due to FVlll hyperproduction in a region of Western Siberia.

[Laboratory monitoring of recombinant factor VIIA effects].

Recombinant activated factor Vll originally proposed to prevent and arrest bleedings in patients with the inhibitory form of hemophilia has been shown to be a universal hemostatic agent that is effective in arresting and preventing a broad spectrum of spontaneous and postoperative hemorrhages. Procedures for monitoring the action of this agent on the hemostatic system have not been studied so far. The paper presents the results of a study of various parameters of the hemostatic system in patients with profuse hemorrhages before and after the use of recombinant activated factor VII.